These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 10358185

  • 1. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
    Soo Hoo W, Lundeen KA, Kohrumel JR, Pham NL, Brostoff SW, Bartholomew RM, Carlo DJ.
    J Immunol; 1999 Jun 15; 162(12):7343-9. PubMed ID: 10358185
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA, McLean CS, Boursnell ME, Martin G, Holmes CL, Reeder S, Entwisle C, Blakeley DM, Shields JG, Todryk S, Vile R, Robins RA, Rees RC.
    Cancer Res; 2000 Mar 15; 60(6):1663-70. PubMed ID: 10749137
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 15; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 10. Genetically engineered tumor cell vaccine in a head and neck cancer model.
    Couch M, Saunders JK, O'Malley BW, Pardoll D, Jaffee E.
    Laryngoscope; 2003 Mar 15; 113(3):552-6. PubMed ID: 12616213
    [Abstract] [Full Text] [Related]

  • 11. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.
    Cancer Res; 2001 Nov 01; 61(21):7925-33. PubMed ID: 11691814
    [Abstract] [Full Text] [Related]

  • 12. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.
    Teshima T, Mach N, Hill GR, Pan L, Gillessen S, Dranoff G, Ferrara JL.
    Cancer Res; 2001 Jan 01; 61(1):162-71. PubMed ID: 11196155
    [Abstract] [Full Text] [Related]

  • 13. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
    Nakamura M, Iwahashi M, Nakamori M, Ueda K, Matsuura I, Noguchi K, Yamaue H.
    Clin Cancer Res; 2002 Aug 01; 8(8):2742-9. PubMed ID: 12171908
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.
    Armstrong CA, Botella R, Galloway TH, Murray N, Kramp JM, Song IS, Ansel JC.
    Cancer Res; 1996 May 01; 56(9):2191-8. PubMed ID: 8616871
    [Abstract] [Full Text] [Related]

  • 15. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
    Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW.
    J Immunol; 1996 May 15; 156(10):3858-65. PubMed ID: 8621924
    [Abstract] [Full Text] [Related]

  • 16. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL, Luckenbach MW, Fischer BJ, Niederkorn JY.
    J Immunol; 1987 Jun 15; 138(12):4515-23. PubMed ID: 3108394
    [Abstract] [Full Text] [Related]

  • 17. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M, Orosz CG, Bach FH.
    J Immunol; 1984 Jun 15; 132(6):3218-25. PubMed ID: 6202778
    [Abstract] [Full Text] [Related]

  • 18. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
    Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G.
    Cancer Res; 2000 Jun 15; 60(12):3239-46. PubMed ID: 10866317
    [Abstract] [Full Text] [Related]

  • 19. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity.
    Gordon LB, Nolan SC, Cserr HF, Knopf PM, Harling-Berg CJ.
    J Immunol; 1997 Sep 01; 159(5):2399-408. PubMed ID: 9278331
    [Abstract] [Full Text] [Related]

  • 20. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor.
    Fioretti F, Fradelizi D, Stoppacciaro A, Ramponi S, Ruco L, Minty A, Sozzani S, Garlanda C, Vecchi A, Mantovani A.
    J Immunol; 1998 Jul 01; 161(1):342-6. PubMed ID: 9647242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.